What is the Infectious Disease Immunoassay Market Size in 2026?
The global infectious disease immunoassay market size was accounted for USD 2.88 billion in 2025 and is predicted to increase from USD 3.22 billion in 2026 to approximately USD 8.87 billion by 2035, expanding at a CAGR of 11.90% from 2026 to 2035.The rising prevalence of infectious diseases, the urgent need for diagnosis, prevention, and treatment, and the expansion of diagnostic centers upsurge the importance of immunoassays.
Key Takeaways
- North America dominated the market in 2025, with a share of approximately 34.8%.
- Asia-Pacific is expected to grow at the fastest CAGR in the infectious disease immunoassay market during the forecast period.
- By product type, the reagents and kits segment held a dominant position in the market with a share of 56.8% in 2025.
- By product type, the software and data management solutions segment is expected to grow at the fastest CAGR of 12.3% in the market between 2026 and 2035.
- By technology, the chemiluminescent immunoassay segment led the global market with a share of 34.6% in 2025.
- By technology, the multiplex immunoassay segment is expected to grow with the highest CAGR of 13.4% in the market during the studied years.
- By test type, the antibody detection immunoassays segment registered its dominance over the global infectious disease immunoassay market with a share of 24.8% in 2025.
- By test type, the combined antigen and antibody immunoassays segment is expected to expand rapidly in the market with a CAGR of 10.8% in the coming years.
- By disease type, the hepatitis immunoassays segment dominated the global market with a share of 23.8% in 2025.
- By disease type, the respiratory infection immunoassays segment is expected to witness the fastest growth in the market with a CAGR of 10.1% over the forecast period.
- By application, the diagnostic testing segment held the largest revenue share of 38.7% in the market in 2025.
- By application, the epidemiological surveillance segment is expected to gain the highest market share with a CAGR of 12.1% between 2026 and 2035.
Infectious Disease Immunoassay: Rising at the Forefront of Modern Healthcare
The infectious disease immunoassay market encompasses a wide range of reagents, kits, assay consumables, calibrators, controls, analyzers, and associated software used to detect antigens, antibodies, and immune biomarkers linked to viral, bacterial, fungal, and parasitic infections. These diagnostic solutions are extensively utilized across hospitals, diagnostic laboratories, blood banks, clinics, and public health institutions for purposes such as screening, diagnosis, disease surveillance, and treatment monitoring. The market is supported by comprehensive immunoassay test menus and well-established infectious disease testing portfolios integrated into automated diagnostic platforms.
Immunoassays play a central role in modern diagnostics and therapeutic monitoring, serving as essential tools in clinical laboratories, research centers, and point-of-care settings. Commonly used techniques include RT-PCR, enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), fluorescence immunoassays, and lateral flow immunoassays (LFIA). Among these, LFIA has gained widespread adoption due to its rapid turnaround time, ease of use, cost-effectiveness, and portability. These features make it particularly valuable for the detection of infectious diseases, especially in decentralized and resource-limited settings.
How is AI Transforming the Infectious Disease Immunoassay Market?
Artificial Intelligence (AI) is significantly transforming the infectious disease immunoassay market by enhancing diagnostic accuracy, efficiency, and speed. AI technologies leverage advanced capabilities such as pattern recognition, large-scale data processing, and intelligent decision-making to improve the detection and analysis of infectious diseases in both human and veterinary applications.
AI-driven tools are increasingly being used to interpret complex medical and microbiological data, including radiological images and digital assay outputs. This enables more precise and consistent diagnosis, particularly in high-throughput and data-intensive environments. Additionally, AI-enhanced point-of-care testing solutions are improving real-time diagnostics by delivering faster and more reliable results.
Furthermore, AI plays a critical role in pathogen surveillance and outbreak management. Through integration with high-throughput sequencing technologies, AI enables efficient variant tracking, pathogen identification, and epidemiological analysis. These capabilities are essential for early detection, monitoring disease spread, and responding effectively to emerging infectious threats.
Overall, the integration of AI is driving innovation in immunoassay-based diagnostics, supporting more accurate, scalable, and responsive healthcare systems worldwide.
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 2.88 Billion |
| Market Size in 2026 | USD 3.22 Billion |
| Market Size by 2035 | USD 8.87 Billion |
| Market Growth Rate from 2026 to 2035 | CAGR of 11.90% |
| Dominating Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Product Type, Technology, Test Type, Disease Type, Application, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Regional Insights
North America holds the largest share of the infectious disease immunoassay market, driven by its well-established healthcare infrastructure, high diagnostic testing volume, and early adoption of advanced technologies. The United States leads the region, supported by strong investments in research and development, widespread use of automated immunoassay platforms, and a high prevalence of infectious diseases. Additionally, the presence of major diagnostic companies and robust public health surveillance systems continues to strengthen market growth.
Europe represents a significant portion of the global market, supported by advanced healthcare systems and strong regulatory frameworks. Countries such as Germany, the United Kingdom, and France are key contributors, with increasing adoption of high-throughput immunoassay technologies and laboratory automation. The region also benefits from government initiatives focused on disease monitoring, early diagnosis, and improved healthcare access, which are driving demand for accurate and efficient diagnostic solutions.
Asia-Pacific is expected to witness the fastest growth in the infectious disease immunoassay market, fueled by rising population levels, increasing healthcare expenditure, and growing awareness of early disease detection. Countries such as China, India, and Japan are leading adoption, supported by expanding healthcare infrastructure and increased access to diagnostic services. The region is also experiencing a higher burden of infectious diseases, which is accelerating the demand for rapid and cost-effective immunoassay solutions, particularly in point-of-care and decentralized settings.
Latin America is emerging as a growing market, with countries such as Brazil and Mexico investing in healthcare infrastructure and diagnostic capabilities. The increasing prevalence of infectious diseases and rising focus on public health initiatives are supporting the adoption of immunoassay-based diagnostics. However, limited access to advanced technologies and budget constraints may affect the pace of growth in certain areas.
Infectious Disease Immunoassay Market Value Chain Analysis
Infectious Disease Immunoassay Market Key Players
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd .
- bioMérieux SA
- Siemens Healthineers AG
- Beckman Coulter, Inc.
- QuidelOrtho Corporation
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Sysmex Corporation
- Becton, Dickinson and Company
- DiaSorin S.p.A.
- Fujirebio Holdings, Inc.
- bioLytical Laboratories Inc.
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Ortho Clinical Diagnostics
Segments Covered in the Report
By Product Type
- Reagents and Kits
- Instruments and Analyzers
- Calibrators
- Controls
- Software and Data Management Solutions
By Technology
- Chemiluminescent Immunoassay
- Enzyme-Linked Immunosorbent Assay
- Fluorescent Immunoassay
- Radioimmunoassay
- Rapid Lateral Flow Immunoassay
- Multiplex Immunoassay
By Test Type
- Antigen Detection Immunoassays
- Antibody Detection Immunoassays
- Combined Antigen and Antibody Immunoassays
- Confirmatory Immunoassays
- Quantitative Immunoassays
By Disease Type
- HIV Immunoassays
- Hepatitis Immunoassays
- Respiratory Infection Immunoassays
- TORCH Infection Immunoassays
- Sexually Transmitted Infection Immunoassays
- Gastrointestinal Infection Immunoassays
- Tropical and Vector-Borne Disease Immunoassays
- Healthcare-Associated Infection Immunoassays
By Application
- Screening
- Diagnostic Testing
- Disease Monitoring
- Blood Screening
- Epidemiological Surveillance
By Region
- North America
- Latin America
- Europe
- Asia-pacific
- Middle and East Africa
Get Sample Link: https://www.precedenceresearch.com/sample/8237